跳至主要内容
临床试验/JPRN-UMIN000030930
JPRN-UMIN000030930已完成未知

Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease. - Effect of febuxostat and inosine on Parkinson's disease

StaGen Co. Ltd.0 个研究点目标入组 30 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Patient who requires nearly full assistance in one's daily life, is incapable of walking and standing (2) Patient taking azathioprine, mercaptopurine hydrate, vidarabine or didanosine (3) Patient whose serum creatinine exceeds 1.5 times the upper limit of the reference value or whose AST (GOT) or ALT (GPT) exceeds the upper limit of the reference value in the pre-registration examination (4) Patient who has undergone surgical treatment for Parkinson's disease (5) Patient with a history or a current illness of gout, hyperuricaemia or urolithiasis (6) Patient who has been treated with febuxostat (7) Patient who has a history or a present illness of hypersensitivity / Idiosyncratic reaction (allergy) to a drug or drugs (8) Patient who has used an investigational drug within 30 days before the consent (9) Patient with pregnancy or a possibility of pregnancy, or lactating patient (10) Patient judged inappropriate with other reasons by a principal investigator or a subinvestigator

研究者

发起方
StaGen Co. Ltd.

相似试验